Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Early or Locally Advanced Breast Cancer”

60 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 60 results

Testing effectiveness (Phase 2)Ended earlyNCT04066790
What this trial is testing

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 12
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Large-scale testing (Phase 3)Active Not RecruitingNCT07196774
What this trial is testing

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Who this might be right for
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 740
Testing effectiveness (Phase 2)UnknownNCT04881929
What this trial is testing

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 30
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Testing effectiveness (Phase 2)Looking for participantsNCT04481932
What this trial is testing

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Peking University 104
Testing effectiveness (Phase 2)Looking for participantsNCT07335081
What this trial is testing

CtDNA in HER2+ EBC Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 60
Not applicableAvailableNCT07643831
What this trial is testing

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Who this might be right for
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Genentech, Inc.
Post-approval studies (Phase 4)Looking for participantsNCT05525767
What this trial is testing

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Who this might be right for
Solid Tumor
Hebei Medical University Fourth Hospital 75
Early research (Phase 1)Not Yet RecruitingNCT07601620
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 258
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03735966
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 75
Large-scale testing (Phase 3)Study completedNCT02149524
What this trial is testing

Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Early or Locally Advanced Breast Cancer
Samsung Bioepis Co., Ltd. 875
Large-scale testing (Phase 3)Looking for participantsNCT07797218
What this trial is testing

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Shanghai Jiao Tong University School of Medicine 220
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)UnknownNCT06470347
What this trial is testing

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

Who this might be right for
HER-2 Positive Advanced Breast Cancer
Zunyi Medical College 67
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Large-scale testing (Phase 3)UnknownNCT05673629
What this trial is testing

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd. 552
Next Page